P. Vasey

Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

P. Vasey, Gordon C. Jayson, Amanda Gordon et al. · JNCI Journal of the National Cancer Institute · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +16

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Éric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist et al. · Journal of Clinical Oncology · 2010 · 572 citations

Medicine, Oncology, Pharmacology +17

Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity.

A J McIlwrath, P. Vasey, Gillian M. Ross et al. · PubMed · 1994 · 331 citations

Medicine, Cancer Biology, Oncology +15

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

Andreas du Bois, Anne Floquet, Jae‐Weon Kim et al. · Journal of Clinical Oncology · 2014 · 328 citations · Full text

Medicine, Oncology, Pharmacology +17

The Acquisition of <b> <i>hMLH1</i> </b> Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

Gillian Gifford, P. Vasey, Stanley B. Kaye et al. · Clinical Cancer Research · 2004 · 263 citations

Medicine, Molecular Biology, Oncology +17